Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 69Sarcoma 23Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Lymphoma 9Lymphoma, Non-Hodgkin 8Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma, Large B-Cell, Diffuse 5Neoplasm Metastasis 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Follicular 4Hodgkin Disease 4Sarcoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Colorectal Neoplasms 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Sezary Syndrome 2Recurrence 2Mycosis Fungoides 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Intraocular Lymphoma 2Immunoblastic Lymphadenopathy 2Hematologic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2

Interventions

Magnetic Resonance Spectroscopy 8X-Rays 7Specimen Handling 7Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Biopsy 5ulixertinib 3trametinib 3palbociclib 3larotrectinib 3erdafitinib 3Temozolomide 3tipifarnib 2tazemetostat 2selpercatinib 2olaparib 2ivosidenib 2ensartinib 2dabrafenib 2Vemurafenib 2Topotecan 2Paclitaxel 2Nivolumab 2Lomustine 2LY3023414 2Gemcitabine 2Filgrastim 2varlilumab 1trastuzumab biosimilar HLX02 1sonidegib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Bevacizumab × Lymphoid × Clear all
NCT01954030 2016-02-19

Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure

Duke University

Phase 1 Terminated
17 enrolled
CNSLymphoid

Glioma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡